Reply to Standaert, B. Comment on “Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium”-Reference-Cited by-同舟云学术

Reply to Standaert, B. Comment on “Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium”

Published:2023-11-01 Issue:11 Volume:11 Page:1673
ISSN:2076-393X
Container-title:Vaccines
language:en
Short-container-title:Vaccines

Author:

Postma Maarten J.¹²,Cheng Chih-Yuan³^ORCID,Buyukkaramikli Nasuh C.³,Hernandez Pastor Luis³,Vandersmissen Ine⁴,Van Effelterre Thierry³,Openshaw Peter⁵^ORCID,Simoens Steven⁶^ORCID

Affiliation:

1. Department of Health Sciences, Unit of Global Health, University Medical Center Groningen, University of Groningen, 9713 AV Groningen, The Netherlands

2. Department of Economics, Econometrics & Finance, Faculty of Economics & Business, University of Groningen, 9749 AE Groningen, The Netherlands

3. Janssen Pharmaceutica NV, 2340 Beerse, Belgium

4. Janssen-Cilag NV, 2340 Beerse, Belgium

5. National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK

6. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium

Abstract

We have read the commentary from Baudouin Standaert [...]

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Link

https://www.mdpi.com/2076-393X/11/11/1673/pdf

Reference11 articles.

1. Standaert, B. (2023). Comment on Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium. Vaccines 2023, 11, 990. Vaccines, 11.

2. Postma, M.J., Cheng, C.-Y., Buyukkaramikli, N.C., Hernandez Pastor, L., Vandersmissen, I., Van Effelterre, T., Openshaw, P., and Simoens, S. (2023). Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium. Vaccines, 11.

3. Bergeron, H.C., and Tripp, R.A. (2021). Immunopathology of RSV: An Updated Review. Viruses, 13.

4. Clinical Features, Severity, and Incidence of RSV Illness during 12 Consecutive Seasons in a Community Cohort of Adults ≥60 Years Old;Belongia;Open Forum Infect. Dis.,2018

5. Severe Morbidity and Mortality Associated with Respiratory Syncytial Virus versus Influenza Infection in Hospitalized Older Adults;Ackerson;Clin. Infect. Dis.,2019